Targeted Nanomedicine for Breast Cancer Therapy provides a compilation of treatment approaches for breast cancer, including conventional receptor targeting methods and novel strategies like stimuli responsive methods and tumor micro-environment responsive strategies. This book compiles the most important information on the state-of-the-art therapeutics, including breast cancer biomarkers and design principles of bio-responsive nanosystems. Presented in two parts, sections cover basic and receptor mediated targeting approaches and examine tumor microenvironment mediated approaches. This is a useful book for pharmaceutical scientists and basic and clinical scientists working in the research area of breast cancer and drug discovery both from academics and industry. Worldwide, breast cancer is the most common cancer in women, however, breast cancer therapy is always challenging. This book aims to help researchers remain updated on the most targeted nanomedicine research available.

Encyclopedia of Infection and Immunity, Four Volume Set provides new insights into the interactions between bacteria, fungi, parasites and their hosts. Specific areas of interest include host cellular and immune response to microbes, molecular mechanisms of action of beneficial microbes or host-associated microbial communities, microbial pathogenesis, virulence factors, experimental models of infection, host resistance or susceptibility, and the generation of innate and adaptive immune responses. Comprised of over 200 chapters written and edited by leading experts in the field, this book will serve as a key resource for students, researchers, academics and industry practitioners in the fields of microbiology, immunology, and infectious diseases. More than 100 years after Robert Koch and Louis Pasteur established the microbial etiology of communicable diseases, the field of microbiology is experiencing a second period of rapid growth and expansion, driven by the realization that changes in host-associated microbial communities might be at the root of a broad spectrum of noncommunicable human diseases. These advances follow on the heels of recent progress in high-throughput sequencing technology, which has provided a wealth of information on the human microbiome and its physiological potential.

Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune checkpoints in different types of cancer, immune cocktails in solid tumors, and immune-phenotyping. Additionally, the book presents basic and clinical data on immunoresistance and glycosylation. This book is a valuable source for cancer researchers, medical doctors, clinicians and members of the biomedical field who must understand certain mechanisms to fight cancer that is resistant to immunotherapy.

Sphingolipids in Cancer, Volume 140, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Topics discussed in this updated volume include Mechanisms of ceramide-dependent cancer cell death, Sphingolipids as regulators of autophagy and endocytic trafficking, The role and function of sphingomyelin biosynthesis in the development of cancer, Neutral sphingomyelinases in cancer: Friend or foe?, Sphingolipid rendezvous at the crossroad of NAFLD and senescence, Ceramide signaling and p53 pathways, Sphingolipid regulation of RNA Biology in cancer phenotypes, The role of ceramide-1-phosphate in tumor cell survival and dissemination, and more.

This issue of Hematology/Oncology Clinics will focus on lung cancer; specifically, Genomics in lung cancer; Neoadjuvant and adjuvant therapy for NSCLC; Treatment of locally advanced NSCLC; First line systemic therapy for NSCLC; Second line chemotherapy and beyond for NSCLC; Treatment of EGFR mutant tumors; Treatment of ALK positive tumors; New targets in NSCLC; Immunotherapy; Advances in Small cell lung cancer; and many more!

This issue will include articles on Prehabilitation; Building a survivorship program in cancer rehabilitation; Aerobic and resistive training: pragmatic integration in cancer rehabilitation; Alternative exercise traditions in cancer rehabilitation; Cancer treatment induced fibrosis: associated functional morbidity; Cancer-related fatigue: The master disabler; and many more!

This issue of Neuroimaging Clinics of North America focuses on Pediatric Brain Tumors, and is edited by Dr. Lara A. Brandao. Articles will include: Posterior fossa tumors in pediatric patients; Supratentorial tumors in pediatric patients; Brain tumors in the neonate; Pineal region masses in pediatric patients; Sellar and suprasellar tumors in pediatric patients; Extraparenchymal lesions in pediatric patients; Tumor and tumor-like masses in pediatric patients that involve multiple spaces; Neuroimaging of innovative peptide base vaccine therapy in pediatric brain tumors; Advanced MRI in pediatric brain tumors: clinical applications; and much more!

This issue of Hematology/Oncology Clinics of North America is devoted to Neuroendocrine tumors. Articles in this issue include: Pathology Classification of Neuroendocrine Tumors; Clinical Presentation and Diagnosis of Neuroendocrine Tumors; Surgical Management of Gastrointestinal Carcinoid Tumors; Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors; Thymic and Bronchial Carcinoid Tumors; Surgical Management of Pancreatic Neuroendocrine Tumors; Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors; Pheochromocytoma and Paraganglioma; Poorly Differentiated Neuroendocrine Tumors; Role of Somatostatin Analogs in the Treatment of Neuroendocrine Tumors; Peptide Receptor Radiotherapy in the Treatment of Neuiroendocrine Tumors; Hepatic-Directed Therapies in Patients with Neuroendocrine Tumors; and Neuroendocrine Tumor Clinical Trial Interpretation and Design.

This issue of Clinics in Geriatric Medicine, devoted to Geriatric Oncology, is guest edited by Drs. Harvey J. Cohen and Arati V. Rao of Duke University Medical Center. Articles in this issue include: Cancer and Aging: General Principles, Biology and Geriatric Assessment; Cancer Screening in the Elderly; Cancer Survivorship: Management of Long-term Toxicities; Socioeconomic Considerations and Shared Care Models of Older Cancer Care; Palliative Care and Symptom Management; Management of Prostate Cancer in the Elderly; Management of Breast Cancer in the Elderly; Management of Lung Cancer in the Elderly; Colorectal Cancer in the Elderly; Myelodysplastic Syndrome and Acute Myeloid Leukemia in the Elderly; Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders; and Monoclonal Gammopathies and Multiple Myeloma in the Elderly.

This issue of Thoracic Surgery Clinics of North America focuses on Pulmonary Metastasectomy. Articles will include: Biology of Pulmonary Metastases; Preoperative Evaluations and Indications for Metastasectomy; Open Approaches to Pulmonary Metastases: Thoracotomy and Sternotomy; Ablative Approaches for Pulmonary Metastases: RFA, microwave, SBRT; Role of Lymphadenectomy with Pulmonary Metastasectomy; Results of Pulmonary Resection: Colorectal Carcinoma; Results of Pulmonary Resection: Sarcoma and Germ Cell Tumors; Isolated Lung Perfusion; Immunotherapy; Medical Management of Pulmonary Metastases: Is There a Role for Surgery?; Thoracoscopic Management of Pulmonary Metastases; Results of Pulmonary Resection: Other Epithelial Malignancies; Thoracoscopic Lung Suffusion; and more!

This issue provides much needed updates since Dr. Sheinfeld's issue published in 2007. Dr. Lin has assembled expert authors to provide clinicians with the full breadth of clinical updates on testicular cancer. New to this issue are articles on clinical outcomes, survivorship, and several articles on the management of Nonseminomatous Germ Cell Tumors.

This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Joaquin Bellmunt, is devoted to Bladder Cancer. Articles in this issue include: Diagnosis and Staging of Bladder Cancer; Epidemiology of Bladder Cancer; Molecular Biology of Bladder Cancer; Pharmacogenomics in Bladder Cancer; Management of Non-muscle Invasive Bladder Cancer; Non-urothelial Bladder Cancer and Rare Variant Histologies; Management of UUT; New Trends in Surgical Management of Bladder Cancer; Bladder Preservation Strategies; Perioperative Therapy of Bladder Cancer (Neoadjuvant and Adjuvant); First Line Treatment and Prognostic Factors of Metastatic Disease: Platinum Eligible Patients; First Line Treatment of Metastatic Disease: Platinum Ineligible Patients; Salvage Therapy in Metastatic Disease; and Future Directions and Targeted Therapies in Bladder Cancer.

This issue of Thoracic Surgery Clinics is devoted to "Advanced Lung Cancer: Radical Surgical Therapy" and is edited by Dr. Raja M. Flores. Articles in this outstanding issue include: Surgical Resection of Lung Cancer in the Elderly; Extended Chest Wall Resection and Reconstruction in the Setting of Lung Cancer; The Management of Non-Small Cell Lung Cancer with Oligometastases; Lung Resection in Patients with Marginal Pulmonary Function; Surgery for Small Cell Lung Cancer; Bronchial and Arterial Sleeve Resection after Induction Therapy for Lung Cancer; Advanced Lung Cancer: Aggressive Surgical Therapy Vertebral Body Involvement; Pulmonary Resection after Pneumonectomy; Superior Vena Caval Resection in Lung Cancer; Surgical Resection of Non-Small Cell Lung Cancer with N2 Disease; Lung Transplantation for Multifocal Lung Adenocarcinoma; Extended Resections of Non-Small Cell Lung Cancers Invading the Aorta, Pulmonary Artery, Left Atrium or Esophagus: Can They Be Justified?; VATS Lobectomy after Induction Therapy; Extrapleural Pneumonectomy for Pleural Disease; Carinal Resection, and more!

Ook in Engels beskikbaar: Knowledge Beats Cancer
JY HET KANKER! 'n Ystervuis beklem jou hart wanneer jy die diagnose hoor. Ná die skok en ontkenning kom die vrae: Wat gaan nou met my gebeur? Wat is my oorlewingskans?
In Kennis Klop Kanker word die pasiënt, en enigeen wat meer van kanker wil weet, ingelig oor alle fasette van kanker:
Wat kanker presies is en hoe kanker ontstaan
Die omvangsyfer en suksesse van kankerterapieë
Belangrikheid van dieet, noodsaaklike gereelde ondersoeke en selfondersoeke
Die vele vertakkinge en benaderinge van moderne terapieë
Moderne behandelingsmetodes en prognose van algemene kankers (29 tipes)
Deurbrake in molekulêre biologie met minder newe-effekte
Beenmurgstamseloorplanting
Mediane oorlewingstatistiek
Alternatiewe, komplementerende en integrerende terapieë
Pasiëntondersteuning, herstel ná mastektomie, kanker by jongmense en kinders, goeie pynkontrole, versorging van pasiënte met gevorderde kanker
Ondersteuning deur gemeenskapsorganisasies
Skrywer se persoonlike perspektief oor lyding en geloofsgenesing
DIE OUTEUR: Albert Stegmann Alberts is 'n onkoloog wat 33 jaar lank met kankerpasiënte gewerk het. Hy het gespesialiseer in al die vertakkings van kankerterapie. Hy is die outeur van verskeie internasionale publikasies.

This issue of Surgical Oncology Clinics of North America, devoted to Imaging in Oncology, is edited by Dr. Vijay Khatri. Articles in this issue include: Imaging of Central Nervous Tumors; Role of Imaging in Head and Neck Malignancies; Imaging of Thoracic Cavity Tumor; Diagnostic Imaging of Hepatobiliary Malignancies; Recent Advances in Genito-Urinary Tract Tumors; Current Status of Imaging for Adrenal Glands; Radiology of Soft Tissue Tumors; Image-Guided Interventions in Oncology; Imaging of Pancreatic Neoplasms; Imaging of Primary Malignant Tumors of Peritoneal and Retroperitoneal Origin; Breast Tumor Imaging; and Application of Intraoperative Imaging in Oncology.

Knowledge of cutaneous lymphomas has been growing significantly as a result of important discoveries in immunology, molecular biology, and immunohistochemistry. Improved clinical pathologic correlation and follow-up data, as well as the synergistic collaboration among different lymphoma registries and specialists from several academic medical centers have greatly contributed to the understanding of the difficult field of cutaneous lymphoproliferative disorders. While these advances have increased understanding of skin lymphomas, they have also produced an extensive and sometimes confusing litany of articles, studies, and classification schemes. This issue on Cutaneous Lymphomas in Surgical Pathology Clinics provides an organized and updated review of this challenging topic by leading experts. It bridges critical knowledge gaps in the diagnosis of cutaneous lymphomas. Sezary Syndrome, Mycosis Fungoides and variants are presented along with B-cell, CD30, lymphoproliferative disorders among others. In addition to multiple clinical and microscopic images, tables and algorithms are presented to aid in diagnosis and staging. Beyond its usefulness to general pathologists, dermatopathologists, and hematopathologists, this information is intended to be helpful for dermatologists, hematologists/oncologists, fellows, and residents.

Cancer can affect people of all ages, and approximately one in three people are estimated to be diagnosed with cancer during their lifetime. Extensive research is being undertaken by many different institutions to explore potential new therapeutics, and biomaterials technology is now being developed to target, treat and prevent cancer. This unique book discusses the role and potential of biomaterials in treating this prevalent disease.
The first part of the book discusses the fundamentals of biomaterials for cancer therapeutics. Chapters in part two discuss synthetic vaccines, proteins and polymers for cancer therapeutics. Part three focusses on theranosis and drug delivery systems, whilst the final set of chapters look at biomaterial therapies and cancer cell interaction.
This extensive book provides a complete overview of the latest research into the potential of biomaterials for the diagnosis, therapy and prevention of cancer. Biomaterials for cancer therapeutics is an essential text for academics, scientists and researchers within the biomedical industry, and will also be of interest to clinicians with a research interest in cancer therapies and biomaterials.
A complete overview of the latest research into the potential of biomaterials for the diagnosis, therapy and prevention of cancerDiscusses the fundamentals of biomaterials for cancer therapeuticsDiscusses synthetic vaccines, proteins and polymers for cancer therapeutics

Remarkable advances have occurred since the Series 3 Fascicle published in 1995 with paradigm shifts in every dimension of our understanding of lung tumors including clinical, radiologic, histopathologic, cytopathologic, immunohistochemical, molecular and therapeutic aspects. The molecular revolution leading to effective targeted therapies and breakthroughs in immunotherapy for lung cancer have led to novel approaches incorporating the concept of personalized medicine for patients who historically had little hope. These advances have strengthened the place of pathologists to play a central role in the multidisciplinary team that is now needed to properly diagnose and manage lung cancer patients.

The biological function of clusterin (CLU, also known as ApoJ, SGP2, TRPM2, CLI) has been puzzling researchers since its discovery and characterization in the early 1980s. Approaches such as cloning, expression and functional characterization of the different protein products generated by the CLU gene have now produced a critical mass of information of tremendous biological importance that are teaching us an important lesson in molecular biology of gene expression regulation. This volume brings together the contributions of top researchers in the field, providing an overview and synthesis of the latest thought and findings relating to CLU.

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics, including platelet-derived growth factor in disease, genetic predisposition in tumor development, primary effusion lymphoma, and many more.
Cancer is not one disease, but a group of diseases in which malignant cells grow out of control and spread to other parts of the body. Eventually these cells form a visible mass or tumor. Appropriate treatment for cancer depends on what kind of cancer a person has. The type of cancer is determined by the organ the cancer starts in, the kind of cell from which it is derived, and the appearance of the cancer cells.

After her diagnosis of triple negative breast cancer (TNBC), health journalist Patricia Prijatel did what any reporter would do: start investigating the disease, how it occurs, and how it's treated. While she learned that important research was emerging, she found a noticeable lack of resources on the disease, which affects 70,000 women a year and differs from hormone-positive breast cancer in important ways, including prognosis and treatment options. Hormone negative breast cancer disproportionately affects younger women and African-American women - and it can be more dangerous than other types of breast cancer. But there are many reasons to be hopeful, as Prijatel learned. Through her blog, Positives About Negative, she has met hundreds of women who have told her their stories and shared their fears, confusion, and frustration. After her recovery, she began writing this book to provide the first dedicated resource for women diagnosed with TNBC. Surviving Triple Negative Breast Cancer delivers research-based information on the biology of TNBC; the role of genetics, family history, and race; how to navigate treatment options; and a plethora of strategies to reduce the risk of recurrence, including diet and lifestyle changes. In clear, approachable language, Prijatel provides an accessible guide to understanding a pathology report and a vast array of scientific studies. Woven throughout the book are stories of women who have faced TNBC. These are mothers, wives, daughters, and sisters who went through a variety of medical treatments and then got on with life - one competes in triathlons, two had babies after being treated with chemo, one got remarried in her 50s, and one just celebrated the 30th birthday of the son she was nursing when she was diagnosed. With honesty and humor, Prijatel's inspiring story shows the heart of a survivor. Her message is that TNBC is a disease to take seriously, with proper and occasionally aggressive treatment, but it is not automatically a killer. Most women diagnosed with the disease do survive. Surviving Triple Negative Breast Cancer is a roadmap for women who want to be empowered through their treatment and recovery.

This is the most comprehensive review of the idiotypic network available. All the current knowledge of idiotypes of the various antibodies is incorporated in this volume. The pathogenic role of idiotypes in autoimmunity and cancer is reviewed in depth. The therapeutic part focusses on harnessing anti-idiotypes for treating autoimmunological disorders, and on the employment of idiotypes for vaccines in cancer and infectious diseases, as well as explaining the manipulation of the idiotypic network in autoimmunity and cancer idiotypes and vaccines.

How does a pathologist become interested and develop expertise in testicular and paratesticular neoplasms, which are relatively uncommon? The truth is simple-the opportunity to see many cases. The authors of this 5th Series Fascicle have such expertise and share a remarkable range of cases from their institutions as well as from many pathologists throughout the world who have sent them cases in consultation over the years. This fascicle is rich source of material that will be a great resource for practicing pathologists and pathologists in training.

It started with a simple question: How can we help them? It became an international movement called NEGU: Never Ever Give Up. When Jessica Joy Rees was diagnosed with an inoperable brain tumor at age 11, she chose to focus not on herself but on bringing joy and hope to other children suffering from cancer. During the ten months she battled cancer, she and her family worked in the "Joy Factory" (originally their garage) making JoyJars (R)-packages filled with toys, games, and love for other kids with cancer. Jessie first handed them out personally at the hospital where she was being treated, but the effort blossomed quickly and there were soon thousands of JoyJars (R) being distributed across the United States and to over fifteen countries. Today, more than 100,000 kids have received JoyJars (R), and they continue shipping each week to kids in over 200 children's hospitals and 175 Ronald McDonald Houses. Jessie lost her battle with cancer in January 2012, but her message lives on in the Jessie Rees Foundation, which has become a beacon of hope for families fighting pediatric cancer. Join the movement at www.negu.org.